Clinical Report: Effectiveness of Pharmacological Treatments in Pediatric MASLD

Overview

This systematic review and network meta-analysis evaluates the efficacy and safety of pharmacological treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) in pediatric patients. The findings highlight the need for further research to establish effective pharmacologic interventions alongside lifestyle modifications.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition in children, closely linked to the rising rates of childhood obesity and metabolic syndrome. The condition can progress to more severe liver diseases, making effective management crucial. Current treatment guidelines emphasize lifestyle changes, but pharmacological options remain underexplored and not universally accepted.

Data Highlights

No numerical data available in the article.

Key Findings

• MASLD prevalence is estimated at 7.6% in the general pediatric population and 34.2% in obesity clinics.
• Key risk factors for MASLD include obesity, type 2 diabetes, and sedentary lifestyles.
• Vitamin E has shown promise in improving histological parameters but not liver enzyme levels.
• Orlistat has demonstrated significant improvements in pediatric MASLD in randomized controlled trials.
• There is currently no universally accepted pharmacologic treatment for pediatric MASLD.

Clinical Implications

Expand on the implications of the lack of pharmacological treatments and suggest future research areas.

Conclusion

The findings from this review highlight the urgent need for targeted pharmacological interventions in pediatric MASLD management, complementing lifestyle changes to improve patient outcomes.

References

1. AASLD, Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease, 2024 -- Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
2. JAMA, Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents, 2011 -- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents
3. Journal of Gastroenterology, Comprehensive Review and Meta-Analysis: Factors Affecting the Interpretation of Clinical Trial Outcomes in Non-Alcoholic Fatty Liver Disease, 2022 -- Comprehensive Review and Meta-Analysis: Factors Affecting the Interpretation of Clinical Trial Outcomes in Non-Alcoholic Fatty Liver Disease
4. Frontiers in Endocrinology — Childhood and Adolescent Metabolic-Associated Steatotic Liver Disease: A Comprehensive Review of Epidemiology, Risk Factors, and Screening Strategies with Focus on Sub-Saharan Africa
5. The New Gastroenterologist — International Agreement Enhances Management of MASLD and MASH
6. Journal of Gastroenterology — Pharmacological Approaches for Managing NAFLD and NASH: Present and Future Perspectives
7. International Agreement Enhances Management of MASLD and MASH
8. Pharmacological Approaches for Managing NAFLD and NASH: Present and Future Perspectives
9. Childhood and Adolescent Metabolic-Associated Steatotic Liver Disease: A Comprehensive Review of Epidemiology, Risk Factors, and Screening Strategies with Focus on Sub-Saharan Africa
10. Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD
11. Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial | Adolescent Medicine | JAMA | JAMA Network